<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305135</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-AZA-IDA-09</org_study_id>
    <nct_id>NCT01305135</nct_id>
  </id_info>
  <brief_title>Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive escalating doses of ldarubicin combined to Azacitidine given at the
      FDA/EMEA approved Schedule and dosing.

      For the Phase I study :

      Determine the safety and tolerance of escalating doses of Idarubicin combined to Azacitidine
      in patients with INT-2 or higher risk MDS.

      For the phase II study:

      Primary: Evaluate rate and duration of response (according to IWG 2006 criteria and IWG 2000
      criteria) to the combination of Idarubicin and Azacitidine in patients with INT-2 or higher
      risk MDS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive ldarubicin combined to Azacitidine.

        -  The first 10 patients will receive Idarubicin 5 mg/m2/d on day 8 of each cycle of
           Azacitidine 75 mg/m2/d CI during 7 days (First Cohort ).

        -  Progression or not to the next cohort of 10 patients : Idarubicin 10 mgm2/d on day 8 of
           each cycle of Azacitidine 75 mg/m2/d CI during 7 days (Second cohort of 10 patients),
           will be decided after completion of the first cohort, after review of hematological
           toxicity by an independent safety review committee (SRC).

        -  The next 21 patients will be treated either according to the first or second cohort
           schedule of Idarubicin, after review of hematological toxicity and efficacy by an
           independent safety review committee (SRC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2010</start_date>
  <completion_date type="Actual">May 9, 2016</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determined tolerance and dose limiting toxicities to idarubicin and azacitidine association.</measure>
    <time_frame>After 12 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to determined overall response rate and response duration</measure>
    <time_frame>After six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>High Grade Myelodysplastic Syndrome Lesions</condition>
  <arm_group>
    <arm_group_label>azacitidine 75mg/m²/d + idarubicin 5mg/m²/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase I : palier 1 have 10 patients and palier 2 have to 10 patients.
palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine and idarubicin</intervention_name>
    <description>azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8</description>
    <arm_group_label>azacitidine 75mg/m²/d + idarubicin 5mg/m²/d</arm_group_label>
    <arm_group_label>Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of MDS, or CMML with WBC &lt; 13,000/mm3 that meets IPSS criteria
             for intermediate-2 or high-risk disease,

          -  IPSS score ≥1.5

          -  Myocardial function do not contraindicate the use of idarubicin

          -  Age ≥ 18 years

          -  Performance Status ≤2 according to ECOG.

          -  Serum creatinine &lt; 1.5 x ULN and normal levels of electrolytes (serum sodium 136-145
             mmol/l, Potassium 3,5-4,5 mmol/l, alkaline Reserve 23-29 mmol/l, , Calcium 2,15-2,5
             mmol/l, Phosphore 0,87-1,45 mmol/l) Serum aspartate aminotransferase (AST)/serum
             glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate
             pyruvate transaminase (SGPT) &lt; 1.5 x upper limit of normal (ULN)

          -  Serum total bilirubin &lt; 1.5 x ULN.

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Signed informed consent.

        Female subjects of childbearing potential must:

        • Accept effective contraception without interruption throughout the duration of study and
        up to three months after the end of treatment.

        Male subjects must

          -  Agree to use condoms throughout study drug therapy, during any dose interruption and
             for one week after cessation of study therapy and up to three months after the final
             treatment if their partner is of childbearing potential and has no contraception.

          -  Agree to learn the procedures for preservation of sperm

        Exclusion Criteria:

          -  Uncontrolled infection

          -  Prior therapy with anthracycline for MDS.

          -  Eligible for an allogeneic stem cell transplantation.

          -  Prior therapy with demethylating agents within the last 3 months

          -  Prior therapy with Hematopoietic growth factor (ESA or G-CSF) agents or cytotoxic
             agents (oral chemotherapy, low doses AraC) within the last 30 days.

          -  Prior history of malignancy other than MDS (except basal cell or squamous cell
             carcinoma or carcinoma in situ of the cervix or breast)

          -  Pregnant or lactating females

          -  Known HIV-1 positivity

          -  Contra-indication to Anthracyclines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel ADES, PHD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GFM: Groupe Francophone des Myélodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <state>Bordeaux - Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la cote basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Hôpital d'enfants</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE, Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital saint louis - Hématologie Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Hématologie Séniors</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Périgueux</name>
      <address>
        <city>Périgueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital PURPAN - Hématologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valence</name>
      <address>
        <city>Valence</city>
        <zip>26953</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Aziza Othmana</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelodysplastic syndrome, azacitidine, idarubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

